GSK curbs Tykerb against Herceptin but combo tests continue
This article was originally published in Scrip
Executive Summary
GlaxoSmithKline has halted one arm of a four-arm study of adjuvant lapatinib (Tykerb/Tyverb) in HER2-positive early-stage breast cancer after early results indicated that when used alone it is unlikely to show non-inferiority to trastuzumab (Roche's Herceptin).